查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2014531

女性用避孕藥市場：依產品類型、作用機制、最終用戶年齡及通路分類－2026-2032年全球市場預測

Female Contraceptive Market by Product Type, Mechanism, End User Age, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，女性避孕藥具市場價值將達到 105.7 億美元，到 2026 年將成長至 112.8 億美元，到 2032 年將達到 175.3 億美元，複合年成長率為 7.49%。

主要市場統計數據
基準年 2025 105.7億美元
預計年份：2026年 112.8億美元
預測年份 2032 175.3億美元
複合年成長率 (%) 7.49%

策略性介紹，概述了影響女性用避孕決策的臨床進展、相關人員的優先事項和獲取限制。

在臨床創新、醫療服務提供者實踐轉變以及患者期望不斷變化的影響下，女性避孕領域正經歷快速的變化。本報告首先簡要概述了當前形勢，重點介紹了影響所有醫療機構避孕服務取得和應用的臨床方法、分銷現狀、監管壓力和實際限制。該報告還將避孕器材和藥物選擇的最新進展與醫療服務提供者的偏好和患者的決策趨勢相結合，為企業高管和臨床領導者提供了實用的理論基礎。

對臨床、監管和數位領域的整合如何重塑整個醫療保健環境中的避孕實踐和患者就醫途徑進行分析概述。

女性避孕格局正受到一系列變革性因素的重塑，這些因素正在改變臨床實踐、產品研發和病患選擇。新型醫療設備設計與長效製劑的出現，拓展了不同生育階段的臨床選擇，迫使臨床醫師重新思考諮商流程與追蹤方案。同時，數位健康工具和遠端醫療也開始改變避孕諮詢、處方和追蹤的提供方式，減少了地理限制，並增強了患者在選擇避孕方法方面的自主權。

對 2025 年關稅調整將如何影響避孕藥俱生產和分銷的供應鏈、籌資策略和價格壓力進行全面分析。

在2025年的政策環境下，影響進口醫藥原料和醫療設備組件的關稅調整訂定，這些變化對採購、價格趨勢和供應鏈結構產生了複雜的影響。使用國際採購的植入式醫療設備電子元件製造商以及依賴海外生產的醫藥活性成分的製造商立即面臨利潤率壓力，引發了關於近岸外包、供應商多元化和庫存策略的討論。為此，採購負責人和醫院系統正在審查與供應商的契約，並考慮建立更長期的採購結構以降低波動風險。

將產品類型、荷爾蒙作用機制、年齡層和分銷管道聯繫起來的詳細細分洞察，揭示了具有臨床和商業性相關性的目標機會。

有效的市場區隔能夠揭示避孕生態系中臨床效益、病患偏好和商業性機會的交會點。產品類型的差異化仍然至關重要。植入、注射劑、子宮內避孕器 (IUD) 和口服避孕藥是核心臨床類別，每種類別都有其獨特的給藥途徑和依從性特徵。在子宮內避孕器中，含銅避孕器和含激素避孕器的差異會影響副作用管理、有效持續時間和醫護人員訓練。口服避孕藥包括複方製劑和單孕激素製劑，其中複方製劑有世代差異。第一代、第二代、第三代和第四代藥物各自具有不同的療效和耐受性，這會影響醫生的處方選擇。

影響美洲、歐洲、中東和非洲以及亞太地區市場准入、監管途徑和分銷策略的關鍵區域趨勢和政策差異。

地理因素影響著各地區的醫療服務取得、監管路徑和競爭行為，獨特的限制和促進因素帶來了不同的挑戰。在美洲，政策辯論、支付方結構和多元化的醫療服務提供者網路為資源豐富的醫療體系中的快速商業化創造了機遇，而服務不足的人群仍然面臨著持續的醫療服務獲取挑戰。儘管地方採購舉措和計劃計畫促進了公共醫療機構的採納，但在高報銷環境下，與私人支付方的談判決定著產品的市場定位。

對製造商、醫療設備專家和靈活的新參與企業如何透過臨床證據、夥伴關係和供應鏈彈性來實現差異化進行實際分析。

競爭格局由成熟的製藥公司、專業的醫療設備製造商以及利用服務和數位生態系統提升產品可及性的新興參與企業組成。主要企業正集中研發精力提升產品的耐受性和易用性，同時投資培訓項目，確保醫護人員能夠正確植入和後續使用醫療器材。製造商與臨床網路之間的策略夥伴關係正逐漸成為加速產品普及的有效途徑，將產品供應與醫護人員培訓和病患支援服務結合。

為製造商和醫療保健系統領導者提供可操作的策略重點，以協調證據產生、彈性供應鏈和管道特定的商業性執行。

產業領導者應採取協作方式，協調各管道的臨床證據創建、供應鏈韌性和商業化過程。首先，應投資於可靠的安全性和耐受性比較數據，這些數據能夠直接解決臨床醫生的擔憂並反映患者相關的治療結果，並將這些證據與簡潔易懂、便於臨床醫生理解的教育模組相結合，從而促進基於器械和長效製劑的治療方案的順利應用。其次，應優先考慮供應商多元化，並探索區域製造投資和契約製造夥伴關係，以降低貿易政策波動和原料成本波動帶來的風險。

高度透明的調查方法，結合對關鍵相關人員的訪談、對監管和臨床證據的審查以及供應鏈分析，可以對策略見解進行多方面的檢驗。

本研究結合了對臨床醫生、採購經理、臨床專案經理和行業高管的定性訪談，以及對監管申報文件、臨床試驗註冊資料和主要衛生機構發布的公共指南的系統性回顧。受訪者的選擇旨在涵蓋不同的地區、醫療機構和角色，從而提供關於臨床實踐、採購考量和患者體驗的平衡視角。次要分析著重於政策公告、價格調整和供應鏈指標，並分析其對製造商和採購商的營運影響。

明確的結論揭示了創新、准入障礙以及將產品進步與臨床影響聯繫起來所需的營運重點之間的關係。

總之，女性用避孕領域面臨臨床創新和系統性可及性挑戰並存的雙重困境，需要採取涵蓋商業性、臨床和營運等多方面的綜合應對措施。儘管器械設計和配方方面的進步拓展了終端用戶的選擇，但其廣泛應用取決於臨床醫生的接受度、分銷能力和報銷柔軟性之間的相互作用。貿易政策的變化和關稅調整使得供應鏈策略和區域生產的重要性日益凸顯，進而影響採購行為和產品定位。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：女性用避孕藥市場：依產品類型分類

  • 植入式避孕器
  • 注射藥物
  • 避孕器
    • 銅子宮內避孕器
    • 荷爾蒙型子宮內避孕器
  • 口服避孕藥
    • 複方藥片
      • 第一代
      • 第四代
      • 第二代
      • 第三代
    • 僅含黃體素的避孕藥

第9章：女性用避孕市場：依機制分類

  • 荷爾蒙系統
    • 複雜類型
    • 單獨使用黃體素
  • 非荷爾蒙系統

第10章：女性用

  • 15-24歲
  • 25-34歲
  • 35-49歲

第11章女性用避孕藥市場：依通路分類

  • 診所
  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章女性用避孕藥市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：女性用避孕藥市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章女性用避孕藥市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國女性用避孕藥市場

第16章：中國女性用避孕市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbvie Inc.
  • Acme Generics Pvt. Ltd.
  • Afaxys, Inc.
  • Agile Therapeutics, Inc.
  • Amneal Pharmaceuticals LLC
  • ASKA Pharmaceutical Co., Ltd.
  • Aurobindo Pharma Limited
  • Bayer AG
  • Church & Dwight Co., Inc.
  • Cipla Limited
  • HLL Lifecare Limited
  • Insud Pharma, SL
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Mayne Pharma Group Limited
  • Merck & Co., Inc.
  • Mithra Pharmaceuticals SA
  • Okamoto Industries, Inc.
  • Organon & Co.
  • Perrigo Company PLC
  • Pfizer Inc.
  • Piramal Pharma Ltd.
  • Reckitt Benckiser Group PLC
  • Ritex GmbH
  • Sanofi SA
  • Say It With A Condom, LLC
  • Syzygy Healthcare Solutions LLC
  • Teva Pharmaceutical Industries Ltd.
  • TherapeuticsMD, Inc.
  • TTK Healthcare Limited
  • Veru Inc.
  • Viatris Inc.
Product Code: MRR-4348D129FB2D

The Female Contraceptive Market was valued at USD 10.57 billion in 2025 and is projected to grow to USD 11.28 billion in 2026, with a CAGR of 7.49%, reaching USD 17.53 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 10.57 billion
Estimated Year [2026] USD 11.28 billion
Forecast Year [2032] USD 17.53 billion
CAGR (%) 7.49%

A strategic introduction that frames clinical advances, stakeholder priorities, and access constraints shaping contemporary female contraceptive decision making

The contraceptive landscape for women is undergoing rapid evolution as clinical innovation, shifting provider practices, and changing patient expectations converge. This report opens with a concise framing of the contemporary environment, highlighting clinical modalities, distribution realities, regulatory pressures, and the practical constraints that shape access and adoption across care settings. It sets a pragmatic intellectual baseline for executives and clinical leaders by integrating recent advances in device and pharmaceutical options with observed patterns in provider preferences and patient decision-making.

The introduction contextualizes the competitive environment by emphasizing how technological improvements, patient-centered care models, and supply chain resilience intersect to determine where investment and operational attention are most valuable. It also clarifies the principal stakeholder groups-manufacturers, clinicians, payors, procurement teams, and patient advocacy organizations-and articulates the decision levers each group controls. Taken together, the framing prepares readers to interpret subsequent sections on structural shifts, policy impacts, segmentation nuances, regional dynamics, and recommended actions.

An analytical overview of the converging clinical, regulatory, and digital forces that are reshaping contraceptive practice patterns and patient access across care settings

The landscape for female contraception is being reshaped by a set of transformative forces that alter clinical practice, product development, and patient choice. New device designs and longer-acting formulations have expanded clinical options for different reproductive life stages, prompting clinicians to rethink counseling workflows and follow-up protocols. Concurrently, digital health tools and telemedicine have begun to change how contraceptive counseling, prescription, and follow-up are delivered, reducing geographic friction and enabling more patient autonomy in method selection.

In addition to technological and care-delivery changes, regulatory pathways and evidence expectations have evolved, raising the bar for clinical data but also creating clearer windows for incremental label expansions and novel indications. Competitive dynamics are shifting as firms pursue differentiated value propositions that emphasize ease of use, side effect profiles, and integrated care experiences rather than simple price competition. Finally, payor approaches and public health priorities are increasingly attentive to equity of access and adherence-support programs, encouraging stakeholders to design solutions that address systemic barriers to consistent, appropriate contraceptive use. Together, these shifts demand integrated commercial and clinical strategies that align product differentiation, reimbursement engagement, and provider education to capture sustained uptake.

A comprehensive analysis of how tariff adjustments in 2025 are reshaping supply chains, procurement strategies, and price pressures across contraceptive manufacturing and distribution

The policy environment in 2025 introduced tariff adjustments affecting imported pharmaceutical inputs and device components, and these changes have had compound effects on procurement, pricing dynamics, and supply chain configurations. Manufacturers that rely on internationally sourced electronic components for insertion devices or on active pharmaceutical ingredients produced abroad have faced immediate margin pressure, prompting discussions about nearshoring, supplier diversification, and inventory strategy. Purchasers and hospital systems have responded by revisiting supplier contracts and exploring longer cadence procurement arrangements to mitigate volatility.

These tariff-driven cost pressures have also influenced product lifecycle decisions. Development teams have increasingly prioritized process efficiencies and supplier consolidation to preserve product viability under higher landed costs. At the same time, public health programs and safety-net providers that operate on constrained budgets have sought supplemental funding models or procurement consortia to maintain access, particularly for long-acting reversible contraceptives that require specialized insertion training and device availability. Importantly, several manufacturers accelerated efforts to localize production of critical inputs and to redesign packaging and logistics to reduce cross-border tariff exposure, thereby enhancing resilience and shortening lead times.

From a demand perspective, clinicians and procurement leaders have indicated that even modest increases in delivered cost can influence method counseling preferences in settings where formularies and procurement guidelines are tightly restricted. Consequently, commercial teams must integrate tariff scenarios into procurement negotiations, pricing strategies, and value communications, highlighting total cost of care, adherence benefits, and downstream savings that resonate with payors and institutional buyers. Transitioning supply chains toward diversification and regional capacity represents a multi-year effort but one that is increasingly prioritized to stabilize access and maintain competitive positioning under shifting trade conditions.

In-depth segmentation insights that connect product types, hormonal mechanisms, age cohorts, and distribution channels to reveal targeted opportunities for clinical and commercial alignment

Effective segmentation illuminates where clinical benefit, patient preference, and commercial opportunity intersect within the contraceptive ecosystem. Product type distinctions remain essential: implants, injectables, intrauterine devices, and pills represent core clinical categories with distinct administration pathways and adherence profiles. Within intrauterine devices, the distinction between copper and hormonal options carries implications for side effect management, duration of effectiveness, and provider training. Pills encompass combined and progestin-only formulations, and within combined options there are generational differences-first, second, third, and fourth generation agents each present unique efficacy and tolerability trade-offs that influence prescriber selection.

Mechanism-based segmentation further clarifies demand dynamics by separating hormonal approaches from non-hormonal choices, and recognizing that hormonal options bifurcate into combined and progestin-only formulations with different contraindication profiles and counseling needs. Age-based end-user segmentation captures life-stage considerations: those aged 15 to 24 prioritize autonomy, convenience, and privacy; the 25 to 34 cohort often balances family planning goals with career and lifestyle considerations; and the 35 to 49 group places greater emphasis on long-term effectiveness, comorbidity considerations, and transition to non-hormonal alternatives as appropriate. Distribution channels shape access pathways, with clinics, hospital pharmacies, online pharmacies, and retail pharmacies each presenting distinct friction points and opportunities for education, adherence support, and aftercare.

Integrating these segmentation lenses reveals where targeted interventions can improve adoption and continuity. For example, long-acting modalities may resonate strongly with older age bands seeking minimal maintenance, while digital counseling and mail-order delivery can substantially lower access barriers for younger users who value discretion. Similarly, tailoring communications to mechanism-specific safety considerations and ensuring that distribution channels are equipped to support insertion or administration are critical operational priorities. By aligning product differentiation, clinical evidence generation, and channel enablement to the intersecting axes of product type, mechanism, age, and distribution, stakeholders can deploy more precise and effective strategies that address both clinical outcomes and user experience.

Key regional dynamics and policy contrasts across the Americas, Europe Middle East Africa, and Asia-Pacific that shape access, regulatory pathways, and distribution strategies

Geographic dynamics influence access, regulatory pathways, and competitive behavior across distinct regions, each presenting unique constraints and enablers. In the Americas, policy debates, payer structures, and diverse provider networks create both opportunities for rapid commercialization in well-resourced systems and ongoing access challenges in underserved populations. Regional procurement initiatives and advocacy programs have shaped uptake in public health clinics, while private payor negotiations dictate product positioning in higher-reimbursement settings.

Europe, Middle East & Africa presents a complex tapestry of regulatory environments and capacity differences. Some countries within this broad region have highly centralized procurement and stringent regulatory harmonization, enabling coordinated rollouts when approvals align. Other markets are fragmented, with variable clinical practice patterns and infrastructure that affect the feasibility of device-dependent contraceptives. Access programs and international donor initiatives remain influential in enabling broader distribution, especially for long-acting reversible methods in low-resource settings.

Asia-Pacific encompasses markets with substantial manufacturing capacity alongside rapidly evolving domestic demand. Regulatory agencies in several jurisdictions have accelerated reviews of contraceptive products and fostered local production capabilities, which can reduce lead times and exposure to international trade perturbations. However, cultural factors, provider practice norms, and heterogeneous reimbursement landscapes continue to shape adoption curves. Across all regions, stakeholders must adapt commercialization strategies to local regulatory structures, distribution ecosystems, and the policy priorities that influence procurement and patient access.

A practical analysis of how manufacturers, device specialists, and agile entrants are differentiating through clinical evidence, partnerships, and supply chain resilience

The competitive environment is populated by a mix of legacy pharmaceutical firms, specialized device manufacturers, and newer entrants leveraging service and digital ecosystems to enhance access. Leading firms focus R&D on improving tolerability and ease of use while investing in training programs to ensure clinician competence for device insertion and follow-up. Strategic partnerships between manufacturers and clinical networks have emerged as a pragmatic way to accelerate adoption, combining product supply with provider education and patient support services.

Smaller, agile companies are differentiating through novel delivery mechanisms, patient engagement tools, and targeted niche strategies aimed at specific age cohorts or clinical subpopulations. Contract manufacturing and component suppliers have also become pivotal players as firms seek to de-risk supply chains and maintain production flexibility. Additionally, procurement consortia and group purchasing organizations have increased their influence by negotiating longer-term supply agreements, which emphasizes the importance of predictable supply and value-based contracting for commercial success.

Across the competitive set, successful companies are those that link product attributes to demonstrable clinical and economic benefits, invest in post-market surveillance and real-world evidence, and create integrated value propositions that include clinician training and patient support. Operational excellence in manufacturing, regulatory strategy, and distribution is equally critical, as disruptions in any of those areas can quickly erode confidence among institutional buyers and clinicians.

Actionable strategic priorities for manufacturers and health system leaders to align evidence generation, resilient supply chains, and channel-specific commercial execution

Industry leaders should pursue a coordinated approach that aligns clinical evidence generation, supply chain resilience, and channel-specific commercialization. First, invest in robust comparative safety and tolerability data that speak directly to clinician concerns and patient-relevant outcomes, and pair that evidence with concise, clinician-friendly education modules to accelerate comfortable adoption of device-based and long-acting options. Second, prioritize supplier diversification and consider regional manufacturing investments or contract manufacturing partnerships to reduce exposure to trade policy shifts and input cost volatility.

Third, tailor go-to-market strategies to distribution realities by enabling clinics with insertion training and stocking solutions, supporting hospital pharmacies with formulary dossiers and total cost of care arguments, and optimizing online channels for privacy-focused younger cohorts through discreet packaging and telehealth-enabled counseling. Fourth, engage proactively with payors and public health purchasers using value narratives that emphasize continuity of care, reduced unintended pregnancies, and lifecycle adherence support rather than unit price alone. Finally, embed real-world evidence programs and post-market safety monitoring to sustain regulatory confidence and to refine product positioning over time. Taken together, these actions create a durable platform for growth that balances clinical credibility with operational resilience and channel effectiveness.

A transparent methodology combining primary stakeholder interviews, regulatory and clinical evidence review, and supply chain analysis to triangulate strategic insights

This research synthesizes primary qualitative interviews with clinicians, procurement directors, clinical program managers, and industry executives, coupled with a structured review of regulatory filings, clinical trial registries, and publicly available guidance from major health authorities. Interview subjects were selected to represent diverse geographies, care settings, and roles to provide a balanced view of clinical practice, procurement considerations, and patient experience. Secondary analysis focused on policy announcements, tariff changes, and supply chain indicators to contextualize operational implications for manufacturers and buyers.

Data synthesis employed thematic analysis to identify cross-cutting trends and causal linkages between policy, supply chain resilience, clinical adoption, and patient behavior. Case studies were used to illustrate successful interventions in provider training, procurement strategies, and channel enablement. Where appropriate, sensitivity considerations were discussed to highlight how changes in trade policy, regulatory requirements, or clinical guidelines could alter recommended priorities. The methodology emphasizes transparency in source types and triangulation across multiple evidence streams to support the strategic recommendations presented in this report.

A decisive conclusion drawing the connections between innovation, access barriers, and the operational priorities necessary to translate product advances into clinical impact

In conclusion, the female contraceptive space presents a blend of clinical innovation and systemic access challenges that require integrated commercial, clinical, and operational responses. Advances in device design and formulation expand options for end users, but adoption depends on the interplay of clinician comfort, distribution capacity, and reimbursement flexibility. Trade policy shifts and tariff adjustments have heightened the importance of supply chain strategy and regional production considerations, which in turn influence procurement behavior and product positioning.

To navigate this environment, stakeholders should prioritize evidence that aligns with clinician concerns, invest in resilient supply chains, and tailor channel strategies to the lived realities of different end-user cohorts. Coordinated cross-functional planning that connects R&D, regulatory affairs, commercial strategy, and supply chain management will be essential to translate product innovations into sustained access and clinical benefit. The insights in this report are intended to inform those decisions and to provide a practical foundation for targeted investments and partnerships.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Female Contraceptive Market, by Product Type

  • 8.1. Implants
  • 8.2. Injectables
  • 8.3. Intrauterine Devices
    • 8.3.1. Copper IUD
    • 8.3.2. Hormonal IUD
  • 8.4. Pills
    • 8.4.1. Combined Pill
      • 8.4.1.1. First Generation
      • 8.4.1.2. Fourth Generation
      • 8.4.1.3. Second Generation
      • 8.4.1.4. Third Generation
    • 8.4.2. Progestin Only Pill

9. Female Contraceptive Market, by Mechanism

  • 9.1. Hormonal
    • 9.1.1. Combined
    • 9.1.2. Progestin Only
  • 9.2. Non-Hormonal

10. Female Contraceptive Market, by End User Age

  • 10.1. 15-24 Years
  • 10.2. 25-34 Years
  • 10.3. 35-49 Years

11. Female Contraceptive Market, by Distribution Channel

  • 11.1. Clinics
  • 11.2. Hospital Pharmacies
  • 11.3. Online Pharmacies
  • 11.4. Retail Pharmacies

12. Female Contraceptive Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Female Contraceptive Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Female Contraceptive Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Female Contraceptive Market

16. China Female Contraceptive Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbvie Inc.
  • 17.6. Acme Generics Pvt. Ltd.
  • 17.7. Afaxys, Inc.
  • 17.8. Agile Therapeutics, Inc.
  • 17.9. Amneal Pharmaceuticals LLC
  • 17.10. ASKA Pharmaceutical Co., Ltd.
  • 17.11. Aurobindo Pharma Limited
  • 17.12. Bayer AG
  • 17.13. Church & Dwight Co., Inc.
  • 17.14. Cipla Limited
  • 17.15. HLL Lifecare Limited
  • 17.16. Insud Pharma, S.L.
  • 17.17. Johnson & Johnson Services, Inc.
  • 17.18. Lupin Limited
  • 17.19. Mayne Pharma Group Limited
  • 17.20. Merck & Co., Inc.
  • 17.21. Mithra Pharmaceuticals S.A.
  • 17.22. Okamoto Industries, Inc.
  • 17.23. Organon & Co.
  • 17.24. Perrigo Company PLC
  • 17.25. Pfizer Inc.
  • 17.26. Piramal Pharma Ltd.
  • 17.27. Reckitt Benckiser Group PLC
  • 17.28. Ritex GmbH
  • 17.29. Sanofi S.A.
  • 17.30. Say It With A Condom, LLC
  • 17.31. Syzygy Healthcare Solutions LLC
  • 17.32. Teva Pharmaceutical Industries Ltd.
  • 17.33. TherapeuticsMD, Inc.
  • 17.34. TTK Healthcare Limited
  • 17.35. Veru Inc.
  • 17.36. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL FEMALE CONTRACEPTIVE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL FEMALE CONTRACEPTIVE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES FEMALE CONTRACEPTIVE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA FEMALE CONTRACEPTIVE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY IMPLANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY IMPLANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY IMPLANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY INJECTABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY INJECTABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COPPER IUD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COPPER IUD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COPPER IUD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL IUD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL IUD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL IUD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY FIRST GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY FIRST GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY FOURTH GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY FOURTH GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY FOURTH GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY SECOND GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY SECOND GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY THIRD GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY THIRD GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PROGESTIN ONLY PILL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PROGESTIN ONLY PILL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PROGESTIN ONLY PILL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PROGESTIN ONLY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PROGESTIN ONLY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PROGESTIN ONLY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 15-24 YEARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 15-24 YEARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 15-24 YEARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 25-34 YEARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 25-34 YEARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 25-34 YEARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 35-49 YEARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 35-49 YEARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 35-49 YEARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. GCC FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GCC FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. GCC FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 165. GCC FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2032 (USD MILLION)
  • TABLE 166. GCC FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2032 (USD MILLION)
  • TABLE 167. GCC FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 168. GCC FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 169. GCC FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2032 (USD MILLION)
  • TABLE 170. GCC FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. G7 FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. G7 FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. G7 FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 192. G7 FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2032 (USD MILLION)
  • TABLE 193. G7 FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2032 (USD MILLION)
  • TABLE 194. G7 FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 195. G7 FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 196. G7 FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2032 (USD MILLION)
  • TABLE 197. G7 FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. NATO FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. NATO FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. NATO FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 201. NATO FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2032 (USD MILLION)
  • TABLE 202. NATO FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2032 (USD MILLION)
  • TABLE 203. NATO FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 204. NATO FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 205. NATO FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2032 (USD MILLION)
  • TABLE 206. NATO FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES FEMALE CONTRACEPTIVE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA FEMALE CONTRACEPTIVE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)